The Science and Politics of Genetically Modified Humans
By Richard Hayes,
Worldwatch
| 07. 01. 2002
July/August 2002
The new human genetic technologies are arguably the most consequential technologies ever developed. Many applications have great potential to prevent disease and alleviate suffering, but others would open the door to a new, high-tech eugenics that could destabilize human biology and undermine the foundations of civil society.
Humanity needs a crash course in the science and politics of the new human genetic technologies. We need to distinguish benign applications from pernicious ones, and we need to adopt policies affirming the former and proscribing the latter. We need to repudiate eugenic political ideologies and deepen our commitment to the integrity of the human species and the dignity of all people. We need to do this on a global scale and within less than a decade.
Two new technologies are of critical concern: reproductive cloning and inheritable genetic modification. Reproductive cloning is the creation of a genetic near-duplicate of an existing person. If I cloned myself, would the child be my son or my twin brother? In truth, he would be neither. He would be a new category of biological...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...